Donate
Lifespan.io > Institutions > Senolytic Therapeutics
×

Menu

Back

Senolytic Therapeutics

http://www.senolytx.com

Organization Description

Senolytic Therapeutics (STX) is developing proprietary strategies to destroy the senescent cells that generate the senescence-associated secretory phenotype (SASP) and harm tissues, thus treating one of the hallmarks of aging and associated age-related diseases.

It has a treatment program focused on removing fibrotic tissue and treating specific kinds of cancer, is working on an immune system-based treatment for cancer cells that have been made senescent through other therapies, and is attempting to discover other compounds that have senolytic effects. The company has offices in Barcelona, Spain, and Boston, Massachusetts and is co-founded by Dr. Manuel Serrano and Dr. Marc Ramis Castelltort. It is a daughter company of Life Biosciences, which owns multiple rejuvenation biotechnology companies each focusing on a different hallmark of aging.

Related Topics

Cellular Senescence is one of the proposed reasons we age.
Why we Age: Cellular Senescence
As your body ages, more of your cells become senescent. Senescent cells do not divide or support the tissues of which they are part; instead, they emit potentially harmful chemical signals, collectively known as the senescence-associated secretory phenotype (SASP), which encourages nearby cells to enter the same senescent state. Their presence causes many problems: they degrade tissue function, increase chronic inflammation, and can even eventually raise the risk of cancer and other age-related ...
Read More
Stay Connected
© 2024 - Lifespan Research Institute
Privacy Policy
Terms Of Use
Sitemap

The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of Lifespan Research Institute/Lifespan.io, its directors, officers or employees.

Powered by MMD